AI-powered drug development company Isomorphic Labs recently announced the completion of a $2.1 billion Series B funding round, led by Thrive Capital with participation from Alphabet and multiple sovereign wealth funds. The funds will be used to advance AI-selected drug candidates into clinical trials and accelerate iterative upgrades of its proprietary platform, IsoDDE. This platform restructures the drug discovery process through artificial intelligence, significantly shortening early-stage R&D cycles. Founded in 2021 and headquartered in London, Isomorphic Labs has established strategic partnerships with multinational pharmaceutical companies such as Novartis, Eli Lilly, and Johnson & Johnson. This funding round is viewed by the industry as a critical milestone in the transition of AI-driven drug development from technological validation to clinical translation, with the potential to drive paradigm shifts in medical R&D and deliver breakthroughs in treating major diseases.